Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence RPPGFSPFR
Primary information
sequence IDSeq_6691
Peptide sequenceRPPGFSPFR
CancerPDF_ID CancerPDF_ID92, CancerPDF_ID739, CancerPDF_ID1089, CancerPDF_ID1889, CancerPDF_ID1890, CancerPDF_ID3226, CancerPDF_ID9454, CancerPDF_ID9455, CancerPDF_ID9935, CancerPDF_ID9936, CancerPDF_ID9968, CancerPDF_ID12743, CancerPDF_ID13996,
PMID16896061,19795908,16395409,21136997,21136997,21136997,26379225,26379225,21124649,21124649,21805675,27058005,20974924
Protein NameBradykinin (and des-Arg bradykinin),Kininogen-1,Bradykinin (and des-Arg bradykinin),Kininogen-1,Kininogen-1,Kininogen-1,Bradykinin,oxidated Bradykinin,Kininogen-1,Kininogen-1,Kininogen-1,Kininogen-1,Kininogen-1
UniprotKB Entry NameBKRB2_HUMAN,KNG1_HUMAN,BKRB2_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN
FluidSerum,Plasma,Serum,Serum,Serum,Plasma,Plasma,Plasma,Serum,Serum,Urine,Serum,Plasma
M/Z1060.57,530.78,1060.57,1059.5614,1059.5614,1059.5614,1060.57,1076.56,NA,NA,1060.5946,1060.627,1060.569
Charge1,2,1,1,1,1,NA,NA,NA,NA,NA,NA,2
Mass (in Da)1060.57,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,1060.2,1076.2,NA,NA,NA
Profiling TechniqueMALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,MALDI-TOF/TOF,MALDI-TOF/TOF,LC-ESI-MS/MS,LC-ESI-MS/MS,MALDI-TOF-MS,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,LC-ESI-MS,NA,NA,NA,NA,NA,NA,NA
Labelled/Label FreeLabel Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Label Free,Labelled,Labelled,Label Free,Label Free,Label Free
FDRNA,less than 7%,less than 1 “5,NA,NA,NA,NA,NA,NA,NA,1,NA,NA
CancerPDF_ID CancerPDF_ID92, CancerPDF_ID739, CancerPDF_ID1089, CancerPDF_ID1889, CancerPDF_ID1890, CancerPDF_ID3226, CancerPDF_ID9454, CancerPDF_ID9455, CancerPDF_ID9935, CancerPDF_ID9936, CancerPDF_ID9968, CancerPDF_ID12743, CancerPDF_ID13996,
p-Value1.00E-05,NA,9.04E-24,NA,NA,NA,NA,NA,1.03E-11,7.39E-10,NA,"0.377,0.304,0.259",NA
SoftwareMASCOT,FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT (v 2.3),MASCOT (v 2.3),NA,NA,NA,Proteome Discoverer,MASCOT and SEQUEST
Length9,9,9,9,9,9,9,9,9,9,9,9,NA
Cancer TypeMetastatic thyroid carcinomas,Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Colorectal cancer,Normal,Colorectal cancer,Colorectal cancer,Breast cancer,Breast cancer,Muscle-invasive bladder cancer,Breast cancer,"Multiple myeloma patients, Acute myeloid leukemia"
DatabaseNCBI refseq Protein Database,NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,SwissProt Database,UniprotKB,UniprotKB,NCBI Protein Database,NCBI Protein Database,SwissProt Database,SwissProt Database,Uniprot database
ModificationNA,NA,NA,NA,NA,NA,NA,Oxidation,NA,Hydroxylated proline at 3rd,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"42 normal, 25 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,30 patients and 30 healthy controls,27 healthy individuals,"94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative","94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",9 BC and 9 control,9 BC and 9 control,751 bladder cancer and 127 control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagn
RegulationNA,NA,"For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =0.77, 0.43 and 1.9 in prostate, bladder and breast cancer respectively",NA,NA,NA,Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. ,Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. ,Differentially expressed between cancer vs control,Differentially expressed between cancer vs control,Differentially expressed between cancer vs normal samples,"Upregulated with the fold change of 0.79 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.82, Upregulated in BC vs healthy with 0.818 fold change",NA
ValidationIndependent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,Leave One out Cross validation,NA,NA,NA,NA,Mann-Whitney tests and areas under receiver-operator characteristic,NA,NA
Sensitivity95% on independent dataset,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Specificity95% on independent dataset,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB